Zhongchao Inc. (ZCMD) स्टॉक विश्लेषण

कंपनी का अवलोकन

Zhongchao Inc. operates within the healthcare sector, specifically serving the Health Information Services industry by delivering healthcare information, education, and training services to professionals under its MDMOOC brand in the People's Republic of China. The company executes its operations through two distinct segments: MDMOOC services and the Sales of Patented Drugs, while also offering patient management services. In terms of scale, the enterprise maintains a market capitalization of $7.42M and reported annual revenue of $11.37M over the trailing twelve months. Although specific employee count data is unavailable, the financial metrics suggest a small-cap entity operating with limited revenue generation relative to its market valuation. The combination of a market cap significantly lower than its annual revenue indicates that the market prices the stock based on asset value rather than earnings power, reflecting the company's status as a micro-cap stock with a price-to-sales ratio of 0.65. This valuation structure implies that investors are assessing the firm primarily through its tangible book value rather than its operational profitability or growth potential.

वित्तीय स्वास्थ्य

The company reported a revenue of $11.37M, yet it recorded a net loss of $-6,310,153 and an EBITDA of $-5,901,042, revealing a cost structure where operating expenses drastically exceed gross profit generation. The gap between the positive revenue and the substantial negative net income highlights severe inefficiencies in covering administrative and operational costs relative to sales. Free cash flow stands at $-1,112,632, indicating that the company is burning cash and lacks the financial flexibility to fund internal expansion or weather economic downturns without external capital injection. The gross margin sits at 45.0%, which provides a baseline of profitability on individual sales before overheads, yet the operating margin of -92.0% and profit margin of -55.5% demonstrate that overhead costs are consuming nearly all gross profits. The balance sheet shows $13.92M in cash against $26,083 in debt, resulting in a debt-to-equity ratio of 0.12, which suggests a highly conservative leverage position despite the operating losses. This liquidity buffer is further supported by a current ratio of 11.11, indicating an exceptionally strong ability to meet short-term obligations with current assets. Return on Equity is -24.9% and Return on Assets is -15.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.

मूल्यांकन आकलन

Both the trailing P/E ratio and forward P/E ratio are listed as N/A due to the company's lack of positive earnings over the trailing twelve months. The absence of a positive P/E multiple implies that traditional earnings-based valuation models are inapplicable, forcing reliance on asset-based metrics instead. The price-to-book ratio is 0.30, indicating that the market values the company at a significant discount to its tangible book value, suggesting the market does not fully value its intangible assets or future service potential. The price-to-sales ratio of 0.65 and EV/EBITDA of 0.42 provide alternative valuation contexts, showing the stock trades at a fraction of its sales and enterprise value multiples, which is typical for distressed or unprofitable small-cap firms. The 52-week high is $12.18 and the 52-week low is $1.44, meaning the current implied price sits well below the recent trading peaks, reflecting a long-term downtrend or market skepticism regarding its turnaround prospects. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index using standard historical data.

Growth & Income

Revenue growth year-over-year is -23.2%, while earnings growth is N/A due to the lack of positive earnings, indicating that the company is contracting in its core business operations. Since earnings are negative, there is no growth trajectory in profitability to analyze against revenue decline, confirming a shrinking operational footprint or declining demand for its health information services. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flows are retained or consumed by operations rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue expansion and zero dividend income, presenting a challenging investment scenario reliant entirely on potential future operational turnaround rather than current income generation or capital appreciation from cash distributions.